Healius (ASX: HLS) to sell Agilex Biolabs to Novotech for A$160m and moves toward net cash

Healius Limited (ASX: HLS) shares rose 5.6% on September 25 after the Sydney-based healthcare group agreed to sell Agilex Biolabs to a subsidiary of Novotech Health Holdings for an enterprise value of A$160 million, a transaction expected to deliver approximately A$155 million in net cash proceeds.

The disposal is expected to complete during the second half of FY27, subject principally to Australian Competition and Consumer Commission and Foreign Investment Review Board approvals. Healius Limited said no material tax liability is expected from the transaction and that completion should move the group into a net-cash position, giving management considerably greater flexibility to invest in its remaining pathology network.

The shares closed at A$0.38, up 5.6%, adding approximately A$13.8 million to Healius Limited’s market capitalisation during a weak broader Australian trading session. The reaction was notable because Agilex Biolabs is not an obviously distressed asset: FY26 revenue increased 14.1% to A$43.6 million and EBITDA rose 67.2% to A$10.7 million.

Why is Healius Limited selling Agilex Biolabs when its earnings are growing?

The answer lies in Healius Limited’s continuing strategic simplification. Agilex Biolabs provides bioanalytical services supporting clinical trials and drug development, whereas the group’s central operating platform is now Australian pathology.

Keeping Agilex Biolabs would give Healius Limited exposure to a growing contract-research business, but it would also leave management running a relatively small operation with different customers, commercial cycles and investment requirements from its national pathology network. The sale effectively exchanges that diversification for cash and a more concentrated corporate structure.

The A$160 million enterprise value equates to approximately 19.8 times Agilex Biolabs’ FY26 pre-AASB 16 EBITDA of about A$8.1 million. That measure differs from the A$10.7 million reported EBITDA because the transaction multiple removes approximately A$2.6 million associated with property-lease accounting.

On that basis, the disposal multiple is substantial for a non-core business. It also gives Healius Limited another opportunity to reduce financial risk at a point when the pathology division still needs operational investment and margin improvement.

How does the A$160 million price compare with what Healius Limited originally paid for Agilex?

The uncomfortable historical comparison is that Healius Limited acquired Agilex Biolabs for approximately A$301 million in December 2021. The latest A$160 million enterprise value is therefore materially below the acquisition price paid less than five years ago.

That does not automatically mean the September 25 transaction destroys A$141 million of current shareholder value. Acquisition accounting, investment made since purchase, business performance, financing effects and the value of cash generated while Healius Limited owned Agilex Biolabs all complicate a simple purchase-price-versus-sale-price comparison.

Even so, the difference illustrates how dramatically Healius Limited’s strategy has changed. Agilex was purchased when the group was broadening its healthcare exposure. The current management strategy is moving decisively in the opposite direction, simplifying around pathology and monetising peripheral businesses.

The sale price also needs to be considered against Healius Limited’s current equity value. At A$0.38 a share after the September 25 rally, the company was capitalised at only about A$261 million. A transaction expected to produce roughly A$155 million of net cash proceeds is therefore exceptionally large relative to the listed company’s market value.

How much will Healius Limited’s balance sheet improve after the sale?

Healius Limited reported net debt of approximately A$32.8 million at the end of FY26. Applying A$155 million of expected Agilex Biolabs net proceeds against that position on a simple basis would leave the company with more than A$120 million of net cash before subsequent operating cash movements, restructuring expenditure or other capital decisions.

That would mark an extraordinary balance-sheet transformation compared with the company that entered the restructuring period carrying substantial leverage.

The earlier sale of Lumus Imaging was the largest step. Healius Limited completed that divestment in May 2026 for approximately A$822 million of cash proceeds, allowing the company to repay its A$680 million syndicated debt facility and support a A$300 million special dividend to shareholders. Agilex Biolabs is now the next major asset to leave the portfolio.

The remaining company becomes much easier to analyse. Instead of valuing pathology, diagnostic imaging and bioanalytical operations under one corporate umbrella, investors will increasingly be valuing an Australian pathology platform whose performance depends on collection volumes, testing mix, labour productivity, reimbursement, automation and cost control.

What business is left inside Healius Limited after Agilex Biolabs is sold?

Pathology is already overwhelmingly the largest operating business. FY26 pathology revenue reached approximately A$1.33 billion, while pathology EBITDA was about A$247.9 million. Group underlying revenue was around A$1.37 billion, showing how small Agilex Biolabs had become relative to the core network despite its higher growth rate.

The business encompasses major brands including Laverty Pathology, Dorevitch Pathology and Queensland Medical Laboratory. Healius Limited operates roughly 1,980 collection centres and 93 laboratories, giving it one of Australia’s largest pathology footprints.

That scale creates an opportunity for significant operating leverage if management can improve efficiency. Pathology has meaningful fixed infrastructure and labour costs, meaning incremental testing volumes can potentially produce stronger margins once collection centres, laboratory capacity and logistics networks are properly utilised.

Healius Limited has been investing in automation, artificial intelligence, digital processes and laboratory productivity. The group also needs to demonstrate that the simplified balance sheet translates into stronger operating performance rather than merely leaving a smaller company with more cash.

Why did Healius Limited shares rise if Agilex Biolabs was one of its faster-growing assets?

Investor sentiment appears to have focused on financial simplification and the sale multiple rather than the loss of Agilex Biolabs’ growth.

A business generating A$8.1 million of pre-AASB 16 EBITDA is being monetised at A$160 million enterprise value, while the listed parent was valued at only about A$261 million after the rally. The resulting A$155 million cash injection is large enough to change Healius Limited’s financial position materially.

That helps explain the share-price response even though Agilex Biolabs grew faster than pathology in FY26. Investors may be assigning more value to removing complexity, eliminating net debt and increasing strategic flexibility than to retaining a relatively small clinical-research subsidiary.

There is still considerable caution embedded in the stock. Healius Limited shares remain far below their 52-week high of A$1.07, reflecting the difficult operating and restructuring history that preceded the current asset sales.

The September 25 move should consequently be viewed as an improvement in sentiment rather than evidence that the broader turnaround is complete.

What becomes the next major test for Healius Limited?

Completion of the Novotech transaction is the first milestone because regulatory approvals still have to be obtained. The expected A$155 million proceeds do not become available simply because a sale agreement has been signed.

After completion, capital allocation becomes the more interesting question. A net-cash pathology company has several options: reinvest in laboratories and technology, return capital, pursue acquisitions or retain balance-sheet capacity for future strategic opportunities.

The higher-quality outcome would be to combine financial simplification with improved pathology economics. Asset sales can make a balance sheet cleaner, but they cannot substitute indefinitely for organic earnings growth.

That is the central September 25 takeaway. Healius Limited is effectively completing its journey from a diversified healthcare group toward a much more focused pathology company. The A$160 million Agilex Biolabs sale strengthens the financial foundation dramatically, but the long-term rerating will depend on what the remaining pathology business earns once the portfolio surgery is finished.